Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.

Emily HibbittsYueh-Yun ChiDouglas S HawkinsFrederic G BarrJulie A BradleyRoshni DasguptaWilliam H MeyerDavid A RodebergErin R RudzinskiSheri L SpuntStephen X SkapekSuzanne L WoldenCarola A S Arndt

Published in: Cancer medicine (2019)

After metastatic status, FOXO1 status is the most important prognostic factor in patients with RMS and improves risk stratification of patients with localized RMS. Our findings support incorporation of FOXO1 status in risk stratified clinical trials.

Keyphrases

clinical trial
prognostic factors
transcription factor
signaling pathway
squamous cell carcinoma
small cell lung cancer
young adults
phase ii
phase iii
childhood cancer